The use of SGLT2 inhibitors (SGLT2i) was associated with fewer gout flares and reduced use of gout medication among adults with both gout and type 2 diabetes (T2D), according to results of a new study.

Since receiving FDA-approval in 2013 as glucose-lowering agents for individuals with T2D, SGLT2i have shown additional benefits in areas including cardiovascular, metabolic, and kidney health.

They have also shown an ability to reduce serum urate levels, and, consequently, gout flares, noted McCormick and colleagues in their study, recently published in Diabetes Care.

Source: MEDspace